Introduction
============

Canine glaucoma is a heterogeneous group of neurodegenerative diseases that lead to progressive retinal ganglion cell death, optic nerve degeneration, and visual field deficits. Intraocular pressure (IOP) is a consistent risk factor for the development of canine glaucoma \[[@r1]\]. Glaucoma is described as primary if it occurs in the absence of an antecedent ocular disease process, such as intraocular inflammation, neoplasia, or lens instability \[[@r2]\]. Primary glaucoma is thought to be caused by unidentifiable and inherent abnormalities in the aqueous humor outflow apparatus of the eye and in adult dogs is further subdivided into primary open angle glaucoma (POAG) and primary closed angle glaucoma (PCAG) based on the appearance of the iridocorneal angle (ICA). In POAG, the IOP is usually pathologically elevated, even in the presence of an open ICA and normal pectinate ligament anatomy in the early disease stages \[[@r3]\]. PCAG, however, is associated with pectinate ligament abnormality (PLA), a form of goniodysgenesis, in several dog breeds \[[@r4]-[@r10]\]. PLA describes the broad sheets of tissue that span the ICA and is associated with increasing age \[[@r11]-[@r14]\]. Although PLA appears to be required, but not sufficient, for the development of PCAG, only a small fraction of dogs with PLA develop PCAG \[[@r15],[@r16]\].

The increased prevalence of primary glaucoma in certain dog breeds implies a genetic etiology. The Basset Hound (BH) is a dog breed known to be affected by POAG and PCAG \[[@r4],[@r17]\]. In common with three other canine breeds, POAG in the BH is an autosomal recessive trait due to a mutation in *ADAMTS17* (Gene ID 170691, OMIM [607511](https://www.ncbi.nlm.nih.gov/omim/?term=607511)) \[[@r17]-[@r20]\]. PCAG, however, is thought to be complex and caused by multiple genetic and environmental factors \[[@r21]-[@r23]\]. Two previous studies of the genetics of PCAG have been reported in the American BH. A genome-wide association study (GWAS) of 37 PCAG cases and 41 controls revealed associations at two novel loci that contain the candidate genes *COL1A2* (Gene ID 1278, OMIM [120160](https://www.ncbi.nlm.nih.gov/omim/?term=120160)) and *RAB22A*(GENE ID 57403, OMIM [612966](https://www.ncbi.nlm.nih.gov/omim/?term=612966)), but no candidate variants were reported \[[@r22]\]. In a subsequent paper, the same group reported a non-synonymous variant in *NEB* (Gene ID 4703, OMIM [161650](https://www.ncbi.nlm.nih.gov/omim/?term=161650)) segregates with PCAG in the BH (BROADD2 chr19:55,885,214 A\>G) \[[@r21]\]. *COL1A2* and *NEB* are promising candidate genes based on their functions. *COL1A2* encodes the pro-α2 chain of collagen type 1 which is an important component of the trabecular meshwork, and previous studies have implicated the role of collagen genes in the pathogenesis of human primary glaucoma \[[@r24]-[@r28]\]. *NEB* encodes the muscle contractility regulating protein, nebulin, which is expressed in the ciliary body musculature, and the belief that muscle-related mechanisms are involved in the aqueous humor outflow pathways makes *NEB* a feasible candidate \[[@r21],[@r29],[@r30]\]. *RAB22A* is known to be an oncogene, and thus, this gene's potential role in primary glaucoma is more difficult to explain \[[@r31]\].

In this study, we investigated the genetic basis of PLA and PCAG in the European BH. First, we tested for a possible association between the reported *NEB* variant and PLA and PCAG. Second, we used a GWAS to identify loci associated with PLA or PCAG and then used an additional cohort of American BHs with PCAG to further evaluate statistically significant associations. We used RNA sequencing (RNA-Seq) to investigate differential gene expression and identify candidate genes in the GWAS-derived loci.

Methods
=======

Genotyping of the *NEB* variant
-------------------------------

The *NEB* variant (BROADD2 chr19:55,885,214 A\>G) reported by Ahram et al. \[[@r21]\] was genotyped in a cohort of 158 BHs (10 PCAG cases, 52 PLA cases, and 96 controls) and 83 non-BH dogs, comprising 31 different breeds, with Sanger sequencing using primers detailed in [Table 1](#t1){ref-type="table"}. The non-BH dogs formed part of a multibreed screening panel that was created before the inception of this study. These dogs had not undergone previous ophthalmological examination.

###### Primer details used for Sanger sequencing of the *NEB* variant.

  **Genomic coordinate of *NEB* variant (CanFam2)**   **Forward primer sequence** **Reverse primer sequence**   **Amplicon size (bp)**   **Annealing temp** **(°C)**
  --------------------------------------------------- --------------------------------------------------------- ------------------------ -----------------------------
  chr19:55,885,214                                    ACCAGTAAGGTGAGTGCTTTCC AGGCTATGATCTCAGAACTGATGC           103                      57

Genome-wide association study
-----------------------------

All DNA samples from privately owned pet dogs were collected following fully informed and written owner consent and with approval from the Animal Health Trust's Research and Ethical Committee (approval number 36--2016). This study was performed in accordance with the ARVO Statement for Use of Animals in Research. DNA samples from American PCAG dogs were provided by one of the coauthors (MK) and included members of a PCAG colony and client-owned dogs all originating within the USA. Dogs were designated as controls or PLA cases based on the results of gonioscopy performed by the primary author (JO), a board-certified veterinary ophthalmologist, and as previously described \[[@r12]-[@r14],[@r32]\]. Dogs were designated as PCAG cases following examination by JO and other board-certified veterinary ophthalmologists. The inclusion criteria for the controls, PLA cases, and PCAG cases were as follows:

1\. Controls: Dogs with normal appearing ICAs aged five years and older.

2\. PLA cases: Dogs with PLA affecting at least 50% of the ICA of each eye. The controls and the PLA cases had IOP within normal limits and normal optic nerve head anatomy as assessed with direct and indirect ophthalmoscopy.

3\. PCAG cases: Dogs with one eye with IOP \>50 mmHg (arbitrary cutoff) without any possible cause of secondary glaucoma and the finding of severe PLA (\>90% of the ICA affected) in the contralateral eye. No diagnostic techniques were performed on the affected eye to confirm closure of the ICA or to assess the pathology of the optic nerve head.

DNA for the GWAS was extracted from buccal mucosal swabs as previously described \[[@r17]\]. Only dogs clear of the published BH POAG mutation were used \[[@r17]\]. DNA samples were submitted at a concentration of 20 ng/μl and a volume of 25 μl to an external laboratory (Neogen; Lansing, MI) for genotyping on the CanineHD BeadChip (Illumina; San Diego, CA) which contains 172,115 single nucleotide polymorphisms (SNPs) \[[@r33]\]. The GWAS data were analyzed using the freely available software package [PLINK](http://pngu.mgh.harvard.edu/~purcell/plink/anal.shtml) \[[@r34]\]. Data were filtered for quality control parameters, including the sample call rate, SNP call rate, and minor allele frequency (MAF). SNPs were excluded from analysis if they had a MAF \<0.05 or had a call rate of \<97%. Individuals were excluded if \>10% SNP genotypes were missing. GWASs were conducted using a standard unadjusted allelic chi-square test for association (1 degree of freedom (df)). Inflation of observed statistics due to relatedness or the population substructure was estimated with genomic control (λ). Data were subsequently corrected for population stratification using a mixed model in the freely available software [GEMMA](http://www.xzlab.org/software/GEMMAmanual) \[[@r35]\]. Five case and control GWASs were performed as detailed in [Table 2](#t2){ref-type="table"}. The p values for each SNP derived from the GWAS using GEMMA were used to create a Manhattan plot for each analysis. A p value of 0.05 after correction for multiple testing using the Bonferroni correction (0.05/number of tests) was the threshold for statistical association in all studies (p\<5.28 × 10^−7^) and prompted further investigation of the associated loci. Associations between the GWAS SNPs and disease in individual dog data sets were assessed using logistic regression using an additive per allele model to compute an odds ratio and confidence interval for the association of one or more SNPs with disease using STATA 10.0 (College Station, TX).

###### Summary of number of dogs, results of quality control filtering steps and correction of population stratification for the five GWAS analyses.

  **Analysis**   **Phenotype of cases**   **Phenotype of controls**   **No. cases**   **No. controls**   **SNPs with MAF \<0.05**   **SNPs with \<0.97 call rate**   **SNPs remaining for analysis**   **λ before correction**   **λ after correction**   **P value**
  -------------- ------------------------ --------------------------- --------------- ------------------ -------------------------- -------------------------------- --------------------------------- ------------------------- ------------------------ --------------
  1              PCAG                     Controls                    24              37                 71,687                     11,749                           96,259                            1.96                      1.04                     1.7×10^−4^
  2              PCAG + PLA               Controls                    81              37                 71,633                     10,166                           97,282                            1.34                      1.00                     7.7×10^−5^
  3              PLA                      Controls                    57              37                 73,253                     11,935                           94,781                            1.28                      1.01                     1.0×10^−4^
  4              PCAG                     PLA                         24              57                 72,150                     9,858                            96,868                            2.23                      1.01                     3.8×10^-7\*^
  5              PCAG                     Controls + PLA              24              94                 71,633                     10,166                           97,282                            2.25                      0.96                     1.4×10^-7\*^

No.=number, λ=lambda (genomic inflation factor), \* denotes significant association (Bonferonni)

Definition of associated loci
-----------------------------

Associated loci were defined based on pairwise linkage disequilibrium (LD) estimates (conservative r^2^ ≥0.5) of the SNPs using the Tagger program embedded in Haploview \[[@r36],[@r37]\]. A list of SNPs in LD with the most strongly associated GWAS SNP for each locus was generated which could denote a region tagged by the GWAS association signal. As for the GWAS, SNPs were excluded from analysis if they had a MAF \<0.05 or a call rate of \<97%.

Gene expression using RNA-Seq
-----------------------------

Eyes were removed from five BHs with PCAG on welfare grounds and from four non-BH dogs with normal eyes that had been euthanized via intravenous overdose of pentobarbitone for reasons unrelated to this study. Following enucleation, each globe was transected along the sagittal plane into two equal halves. Each half globe was immersed in 15 ml RNA*later* solution (Ambion; Foster City, CA) before being stored at −80 °C until later use as previously described \[[@r38],[@r39]\]. RNA was extracted from selected tissue samples using the Qiagen RNAeasy Midi Kit (Qiagen; Hilden, Germany) according to the manufacturer's instructions. Following thawing of each half globe, a section of the ICA was dissected under an operating microscope with microsurgical instrumentation aiming for approximately 200--250 mg tissue. The posterior boundary of the dissected tissue was the posterior pars plana, and the anterior boundary was the corneoscleral limbus. No lens tissue was included in the dissection, but the sclera was included. Adherent conjunctiva and episcleral tissues were removed. Total RNA (20 ng--1 µg per sample, at a concentration of ≥20 ng/μl with RNA integrity number (RIN) ≥8.0 and optical density (OD)260/280 ≥1.8) was submitted to Otogenetics Corporation (Atlanta, GA) for library preparation and sequencing: 1--2 μg of cDNA was generated using the Clontech Smart cDNA kit (Clontech Laboratories; Mountain View, CA) from 100 ng of total RNA. cDNA was fragmented using Covaris (Covaris; Woburn, MA) and profiled using an Agilent Bioanalyzer 2100 (Agilent; Santa Clara, CA). Libraries were prepared using NEBNext reagents (Catalog No. 634,925. New England Biolabs; Ipswich, MA): mRNAs were purified using Poly(A) selection from the total RNA sample and then fragmented. cDNA was then synthesized using random priming, followed by end repair, phosphorylation, A-tailing, adaptor ligation, and finally, PCR amplification. The quality, quantity, and size distribution of the Illumina libraries were determined using an Agilent Bioanalyzer 2100. The libraries were then loaded on an Illumina HiSeq2500 for clustering and sequencing according to the standard operation. Paired-end 90--100 nucleotide reads were generated, and data quality was assessed using FASTQC (Babraham Institute; Cambridge, UK). After optimum quality control (QC) results were achieved, the samples were analyzed. Sequence reads (minimum of 50 M per sample) were mapped to the CanFam3.1 reference genome, and the read count values of gene expression (fragments per kilobase million, FPKM) were calculated. The differential expression of the FPKM (the read counts) between the PCAG cases and controls was calculated as the base 2 log of the fold change of controls/PCAG cases (log~2~ (the FPKM of the PCAG cases/the FPKM of the controls)). The test statistic was used to compute the statistical significance of the observed change in the FPKM. The p value represents the uncorrected p value of the test statistic, and the Q value represents the false discovery rate--adjusted p value of the test statistic. For genes shown to be differentially expressed, their functions and associated phenotypes (for potential candidacy for canine PCAG) were assessed using VarElect [GeneCards](http://varelect.genecards.org)®.

Results
=======

*NEB* variant genotyping
------------------------

One hundred fifty-seven BHs (ten PCAG cases, 52 PLA cases, and 95 controls) were homozygous for the reported *NEB* variant (G/G), and only one control was heterozygous (A/G). In the 83 non-BH dogs, 59 were homozygous for the variant (G/G), 15 were heterozygous (A/G), and only nine were homozygous for the reference allele (A/A). Thus, as well as not being associated with PLA or PCAG, it appeared that the SNP at this location is a common polymorphism, and the reported variant may actually be more common in European dogs than the reference allele.

Genome-wide association studies
-------------------------------

The results of the five GWASs, including case and control designation, filtering steps, the genomic inflation factor, and the p value of the top SNP from each analysis can be found in [Table 2](#t2){ref-type="table"}. Statistically significant SNP associations were found in GWAS Analyses 4 and 5. In Analysis 4 (Cases: PCAG cases; Controls: PLA cases), a SNP on canine chromosome 24 (BICF2G630505097; CanFam3.1 chr24:17,381,226; p = 3.8 × 10^−7^) reached the threshold of genome-wide statistical association ([Figure 1](#f1){ref-type="fig"}). In Analysis 5 (Cases: PCAG cases; Controls: PLA cases and control dogs), an additional SNP in the same region increased the strength of the statistical association further (BICF2P544799; CanFam3.1 chr24:18,739,902; p = 1.4 × 10^−7^; [Figure 2](#f2){ref-type="fig"}).

![Manhattan plot for GWAS Analysis 4 (Cases: PCAG cases; Controls: PLA cases) in the European BH. The horizontal red line denotes the threshold for genome-wide statistical association.](mv-v25-93-f1){#f1}

![Manhattan plot for GWAS Analysis 5 (Cases: PCAG cases; Controls: PLA cases and control dogs) in the European BH. The horizontal red line denotes the threshold for genome-wide statistical association.](mv-v25-93-f2){#f2}

GWAS conditioning on the most strongly associated SNP was performed to assess whether any additional loci were associated with PCAG. To achieve this, SNP BICF2P544799 was introduced as a covariate in the mixed model in Analysis 5. This revealed an additional SNP at a distinct chromosomal location on canine chromosome 37 to reach the threshold of genome-wide statistical association (BICF2P928441; CanFam3.1 chr37: 24,747,131; p = 1.9 × 10^−7^; [Figure 3](#f3){ref-type="fig"}). Conditional analysis using both associated SNPs as covariates in the model revealed no further association signals.

![Manhattan plot for GWAS analysis 5 (Cases: PCAG cases; Controls: PLA cases and control dogs) in the European BH using BICF2P544799 as a covariate. The horizontal red line denotes the threshold for genome-wide statistical association.](mv-v25-93-f3){#f3}

The interrelationships between the three strongest associated SNPs and PCAG risk were further assessed in the individual SNP data sets using logistic regression. This was done for the original GWAS set and with the addition of PCAG cases from the USA. All three SNPs were strongly associated with PCAG, and the strength of association increased following the addition of the American dogs with PCAG to the analyses ([Table 3](#t3){ref-type="table"}). A combined analysis of the two SNPs and the risk of PCAG in all 153 dogs (59 cases and 94 controls defined as [Table 3](#t3){ref-type="table"}) using an additive (per allele) model resulted in an odds ratio of 19.30 (95% confidence interval 7.62--48.85; p = 1.4 × 10^−24^).

###### Association of GWAS top SNPs with PCAG in the BH (Analysis 5 (see [Table 2](#t2){ref-type="table"})

  **Top SNP from GWAS**            **USA PCAG cases included?**   **No. PCAG cases**   **No. PLA cases and controls**   **OR**   **Lower 95% CI**   **Upper 95% CI**   **P-value**
  -------------------------------- ------------------------------ -------------------- -------------------------------- -------- ------------------ ------------------ -------------
  chr24:17381226 BICF2G630505097   No                             24                   94                               13.73    5.06               37.26              4.2×10^−11^
  Yes                              59                             94                   18.84                            7.97     44.51              1.6×10^−21^        
  chr24:18739902 BICF2P544799      No                             24                   94                               28.35    8.50               94.58              1.6×10^−11^
  Yes                              59                             94                   15.81                            6.03     41.45              1.4×10^−12^        
  chr37: 24,747,131 BICF2P928441   No                             24                   94                               18.03    4.44               73.28              1.1×10^−6^
  Yes                              59                             94                   14.76                            4.19     51.96              3.6×10^−8^         

No.=number, OR=odds ratio, CI=confidence interval

Definition of associated loci
-----------------------------

A critical region spanning the top associated SNPs was defined based on pairwise LD of these top three SNPs with other SNPs on the respective chromosome in the GWAS data set. Although the top two chromosome 24 SNPs BICF2G630505097 and BICF2P544799 were correlated at an r^2^ of 0.79 in this study set, they were both used as tag SNPs to ensure coverage. From these analyses, the following chromosomal loci were defined for subsequent investigation: CanFam3.1 chr24:17,381,226--18,739,902 and chr37:24,747,131--24,958,250.

Identification of candidate genes from RNA-Seq
----------------------------------------------

Whole transcriptome data derived from ICA tissues were used to compare differential gene expression between BH PCAG cases (n=5) and non-BH controls (n=4) in the extended loci determined from GWAS and LD analysis ([Table 4](#t4){ref-type="table"}). In the chromosome 24 locus, differential gene expression was present for five genes or loci: *SIGLEC1* (Gene ID 6614, OMIM [600751](https://www.ncbi.nlm.nih.gov/omim/?term=600751)), C24H20orf194, *SLC4A11*(Gene ID 83959, OMIM [610206](https://www.ncbi.nlm.nih.gov/omim/?term=610206)), *PROSAPIP1*(Gene ID 9762, OMIM [610484](https://www.ncbi.nlm.nih.gov/omim/?term=610484)), and *OXT*(Gene ID 5020, OMIM [167050](https://www.ncbi.nlm.nih.gov/omim/?term=167050)). In the chromosome 37 locus, differential expression was present for three genes: *CXCR2*(Gene ID 3579, OMIM [146928](https://www.ncbi.nlm.nih.gov/omim/?term=146928)), *CXCR1*(Gene ID 3577, OMIM [146929](https://www.ncbi.nlm.nih.gov/omim/?term=1146929)) and *ARPC2* (Gene ID 10109, OMIM [604224](https://www.ncbi.nlm.nih.gov/omim/?term=604224)). A survey of the functions and associated phenotypes of these genes revealed no evidence of reported association with glaucoma. All genes, however, appear to be involved in inflammation or immunity ([Table 5](#t5){ref-type="table"}).

###### Differential gene expression results for the BH PCAG loci.

  **Gene**                                 **CanFam3.1 coordinate**   **Status**   **FPKM Controls**   **FPKM PCAG cases**   **log~2~(fold change)**   **Test statistic**   **P-value**   **Q-value**   **Significant?**
  ---------------------------------------- -------------------------- ------------ ------------------- --------------------- ------------------------- -------------------- ------------- ------------- ------------------
  **Locus chr24:17,381,226--18,739,902**                                                                                                                                                                
  LOC100855425                             24:17377802--17459234      OK           3.66177             4.27275               0.222624                  0.105002             0.90045       0.972499      no
  RNF24                                    24:17377802--17459234      OK           13.5062             15.8018               0.226461                  0.549112             0.2461        0.564651      no
  PAX1                                     24:1743907--1752578        NOTEST       0.751058            0.206085              −1.86569                  0                    1             1             no
  PANK2                                    24:17463086--17489560      OK           19.9698             18.2754               −0.127921                 −0.289163            0.55265       0.833548      no
  MAVS                                     24:17511842--17529197      OK           29.2054             32.6664               0.161573                  0.390852             0.42265       0.743935      no
  AP5S1                                    24:17539786--17543605      OK           8.54101             8.52501               −0.00270593               −0.00393991          0.99425       0.998863      no
  CDC25B                                   24:17552205--17561823      OK           12.1744             14.8                  0.28175                   0.556191             0.2447        0.563837      no
  CENPB                                    24:17569396--17572311      OK           31.9742             38.916                0.283456                  0.799702             0.1328        0.393219      no
  SPEF1                                    24:17572374--17578571      OK           1.5338              1.92433               0.327243                  0.400218             0.3999        0.724145      no
  C24H20orf27                              24:17586019--17600147      OK           22.4481             29.0792               0.373394                  0.779776             0.1107        0.352522      no
  HSPA12B                                  24:17600534--17619889      OK           6.57984             9.70452               0.560605                  1.14769              0.0296        0.142427      no
  SIGLEC1                                  24:17636164--17667080      OK           2.18752             12.5593               2.52139                   4.87528              5.00E-05      0.0008345     yes
  ADAM33                                   24:17668462--17682217      OK           10.7869             8.23265               −0.389845                 −0.829875            0.0807        0.285699      no
  GFRA4                                    24:17686816--17690747      OK           3.16594             2.14218               −0.563553                 −0.711984            0.2384        0.555935      no
  ATRN                                     24:17698237--17859816      OK           18.7085             14.7908               −0.338994                 −0.812765            0.08165       0.288073      no
  C24H20orf194                             24:17908366--18050002      OK           14.0202             9.25396               −0.599364                 −1.46229             0.00165       0.0153647     yes
  SLC4A11                                  24:18057411--18068425      OK           28.8724             6.6876                −2.11013                  −4.36281             5.00E-05      0.0008345     yes
  ITPA                                     24:18070979--18082187      OK           11.9247             16.3186               0.452557                  0.814939             0.0945        0.316902      no
  DDRGK1                                   24:18085722--18098868      OK           17.4284             15.1717               −0.200057                 −0.450069            0.33115       0.659854      no
  LOC102157332                             24:18111855--18122295      NOTEST       0.531426            0.412288              −0.366218                 0                    1             1             no
  PROSAPIP1                                24:18111855--18122295      OK           20.0459             12.6993               −0.658565                 −1.63743             0.00105       0.0107012     yes
  FASTKD5                                  24:18124262--18166506      OK           13.9635             14.315                0.0358696                 0.0772293            0.86905       0.965583      no
  CST11                                    24:181590--184213          NOTEST       0                   0                     0                         0                    1             1             no
  AVP                                      24:18183056--18184827      NOTEST       0.182349            0.0787568             −1.21123                  0                    1             1             no
  OXT                                      24:18193380--18194236      OK           18.6151             5.43912               −1.77503                  −2.94744             0.0006        0.0068551     yes
  MRPS26                                   24:18215054--18217105      OK           24.9994             26.2617               0.0710653                 0.176449             0.7648        0.934576      no
  LOC102151131                             24:18217903--18222755      NOTEST       0.0563875           0.0232463             −1.27838                  0                    1             1             no
  LOC102154818                             24:18224354--18395654      NOTEST       0.867838            0.884208              0.0269605                 0                    1             1             no
  PTPRA                                    24:18224354--18395654      OK           30.9735             28.6433               −0.112839                 −0.288467            0.5554        0.835146      no
  VPS16                                    24:18401450--18424606      OK           11.5555             11.6659               0.0137143                 0.0286225            0.95285       0.989023      no
  PCED1A                                   24:18424775--18429698      OK           18.7163             16.9792               −0.140525                 −0.340822            0.5442        0.828421      no
  LOC102155387                             24:18442763--18443512      NOTEST       0.12029             0.206892              0.782359                  0                    1             1             no
  TMEM239                                  24:18443575--18445637      NOTEST       0.308423            0.133061              −1.21283                  0                    1             1             no
  C24H20orf141                             24:18445693--18446873      NOTEST       0.202272            0.317907              0.652307                  0                    1             1             no
  CPXM1                                    24:18453867--18460350      OK           8.40695             13.7502               0.7098                    1.29913              0.0077        0.0506978     no
  EBF4                                     24:18470596--18528305      OK           1.69066             1.6627                −0.0240522                −0.0278686           0.96215       0.991001      no
  IDH3B                                    24:18556489--18561401      OK           46.7683             38.3285               −0.287114                 −0.659815            0.1486        0.420704      no
  NOP56                                    24:18561409--18566780      OK           28.0915             30.953                0.139945                  0.325807             0.48615       0.78904       no
  TMC2                                     24:18577342--18642204      NOTEST       0.308586            0.147869              −1.06136                  0                    1             1             no
  ZNF343                                   24:18661008--18665685      NOTEST       0.245175            0.133892              −0.872746                 0                    1             1             no
  SNRPB                                    24:18674022--18683315      OK           62.0096             61.9386               −0.00165212               −0.004023            0.99365       0.998542      no
  TGM6                                     24:18700241--18721827      NOTEST       0.0171946           0                     \-                        0                    1             1             no
  TGM3                                     24:18753637--18793790      NOTEST       0.0342808           0.138228              2.01158                   0                    1             1             no
  **Locus chr37:24,747,131--24,958,250**                                                                                                                                                                
  RUFY4                                    37:24809358--24830254      OK           1.71109             1.18547               −0.52945                  −0.51443             0.27475       0.599772      no
  CXCR2                                    37:24831509--24846517      OK           3.35508             1.02764               −1.70702                  −1.59836             0.00145       0.013826      yes
  CXCR1                                    37:24861913--24866062      OK           1.82409             0.616257              −1.56557                  −1.58159             0.0041        0.030963      yes
  ARPC2                                    37:24914388--24936198      OK           84.4912             137.67                0.704343                  1.97128              0.00035       0.004435      yes
  GPBAR1                                   37:24940929--24943399      OK           1.26415             2.05007               0.697505                  0.919835             0.14675       0.417894      no
  AAMP                                     37:24943657--24948585      OK           40.9075             43.1513               0.077039                  0.181187             0.70665       0.913414      no
  PNKD                                     37:24948682--25008542      OK           6.30845             7.78033               0.302547                  0.202254             0.70135       0.911242      no

OK=test successful, NOTEST=not enough alignments for testing

###### Details of differentially expressed genes, their functions and associated disorders and phenotypes (assessed using [VarElect GeneCards](http://varelect.genecards.org)®)

  **Gene**      **Gene full name**                                              **Function**                                                                                        **Associated disorders/phenotypes**
  ------------- --------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  *SIGLEC1*     Sialoadhesin                                                    Endocytic receptor mediating clathrin dependent endocytosis                                         Glomerulonephritis Sclerosis X-linked intellectual disability
  C20orf194     Chromosome 20 open reading frame 194                            May act as an effector for ARL3                                                                     HIV-1 Hepatitis
  *SLC4A11*     Solute Carrier Family 4 Member 11                               Transporter which plays an important role in sodium-mediated fluid transport in different organs.   Corneal dystrophy HIV-1 Hepatitis
  *PROSAPIP1*   Proline Rich Synapse Associated Protein Interacting Protein 1   May be involved in promoting the maturation of dendritic spines                                     Hepatitis
  *OXT*         Oxytocin                                                        Contraction of smooth muscle of uterus and mammary gland                                            Persistent genital arousal Endometritis Inhibited male orgasm Epignathus Chorioamnionitis Parturition Lactation
  *CXCR1*       Chemokine (CXC) Receptor 1                                      Neutrophil activation, neutrophil count                                                             HIV-1 Pyelonephritis & urinary tract infections Idiopathic anterior uveitis
  *CXCR2*       Chemokine (CXC) Receptor 2                                      Neutrophil activation, neutrophil count                                                             Congenital neutropaenia Neutrophil migration Pyelonephritis Septicaemia Granulocytic anaplasmosis
  *ARPC2*       Actin Related Protein 2/3 Complex Subunit 2                     Actin filament assembly. Platelet, reticuloycte and neutrophil count                                Platelet, reticuloycte and neutrophil count

Discussion
==========

Canine PCAG is considered complex, likely involving multiple genetic and environmental factors \[[@r40]\]. GWASs have been used extensively in the human field over the last two decades to improve the understanding of the genetic basis of many complex traits by revealing associated susceptibility loci and have provided invaluable insights into the allelic architecture of many multifactorial traits \[[@r41]\]. In humans, GWASs of thousands of individuals are usually required to find significant associations with complex diseases \[[@r42],[@r43]\]. More recently, findings from human GWASs of complex disease have supported the original hypothesis that their genetic architecture is mainly comprised of common variants with modest or intermediate effect, as well as a smaller subset of high-penetrant (familial) low-frequency variants of high effect \[[@r44]\]. In the dog, however, many fewer canine samples are required to detect a statistically significant association compared to human studies, owing to the more limited genomic architecture and haplotype structure of domestic dog breeds \[[@r22],[@r23],[@r45]-[@r47]\]. In the present GWAS, a locus on canine chromosome 24 was found to be associated with PCAG relative to PLA in Analysis 4 using a total of only 81 dogs (24 PCAG cases and 57 PLA cases), and the level of statistical association was further increased when the controls were combined with the PLA cases in Analysis 5 (a total of 118 dogs). An additional locus was found on canine chromosome 37 following conditional analysis. Owing to our employment of correction for population stratification and the stringent threshold for a statistically significant association, it is unlikely that these are false positive associations \[[@r48]\]; in addition, the strength of the associations was augmented by the addition of the American BH PCAG cases. This was particularly marked for BICF2G630505097 which was also the most strongly associated SNP in GWAS Analysis 4 (Cases: PCAG cases; Controls: PLA cases). This SNP is located in an intergenic region (chr24:17,381,226) with *RNF24* (Gene ID 11237, OMIM [612489](https://www.ncbi.nlm.nih.gov/omim/?term=612489); chr24:17,423,245--17,454,478) and *PANK2* (Gene ID 80025, OMIM [606157](https://www.ncbi.nlm.nih.gov/omim/?term=606157); chr24:17,463,603--17,489,677) the nearest upstream genes. These genes may prove to be candidate genes for PCAG as a previous study of a glaucoma-related trait in humans, optic nerve head morphology, revealed a statistically significant linkage signal at the RNF24/PANK2 locus \[[@r49]\].

The present GWAS results did not corroborate those of previous studies in the BH. A GWAS of PCAG in American BHs reported two regions were associated with PCAG \[[@r22]\]. These susceptibility loci were situated on canine chromosomes 14 and 24 (chr14:19,911,001--20,161,358 and chr24:43,091,222--43,595,979) and contained the collagen gene *COL1A2* and oncogene *RAB22A,* respectively. The inability to reproduce these findings in the present GWAS might be related to population differences in the frequency of the risk loci between European BHs and American BHs. Another study in American BHs by the same investigators used linkage analysis followed by exome-sequencing analysis to identify an SNP in *NEB* to segregate with PCAG \[[@r21]\]. The present study, however, did not find any association between this variant and PCAG, and the multibreed genotyping suggested that this variant is a common polymorphism. As the resequencing study that identified this *NEB* variant captured only the exome, it is possible that the variant is tagging a true functional variant underlying the linkage study results \[[@r21]\]. However, although a recessive mode of inheritance was assumed, the logarithm (base 10) of odds (LOD) score was considerably lower than those achieved for other recessive diseases that have been mapped in a similar way \[[@r21],[@r50]-[@r52]\]. Therefore, it is possible that this result was a chance finding; the magnitude of associations identified in the present GWAS, which used stringent correction for multiple testing and a set of American BHs that validated the results, does not support PCAG in the BH to be a recessive disease from the sample set we analyzed; PCAG is more likely to be of complex etiology.

It was interesting that a statistically significant association of SNPs with PCAG was found in Analysis 4 (Cases: PCAG cases; Controls: PLA cases) and not in Analysis 2 (Cases: PCAG and PLA cases; Controls: control dogs). PLA is considered a consistent risk factor for, and therefore, likely to be on the causal pathway to, canine PCAG \[[@r5],[@r9],[@r15],[@r53]\]. Thus, we considered it probable that there are shared genetic factors between PCAG and PLA cases, and a statistically significant association with disease (PCAG or PLA or both) would more likely be discovered when PCAG is analyzed combined with PLA cases against controls owing to the greater number of cases, and thus, power, of such analysis. Instead, these studies revealed two loci that are statistically significantly more common in PCAG cases than in PLA cases and controls. This is not a completely unexpected finding, however, as although PLA is a risk factor for PCAG, only a minority of dogs with PLA develop PCAG. This study supports the theory that PLA is *required* for but is not *sufficient* for PCAG. Thus, it is likely that the two chromosomal loci identified are involved in the trigger of the progression from PLA to PCAG. This finding will influence our ongoing investigations of the allelic architecture of PCAG in the BH. Future investigations to identify causal variants for PCAG in these loci will likely utilize a next-generation whole genome sequencing (WGS) approach using multiple PCAG and PLA cases and subsequent genotyping of segregating variants in extended case-control sets. For complex disease, such as canine PCAG, a relatively large sample set is likely to be needed. Furthermore, the efficiency of a WGS approach will likely be improved by selecting dogs based on a homozygous genotype for the most strongly associated GWAS SNPs.

The main challenge of GWASs in investigating complex disease is to pinpoint possible causal variants underlying association signals as the majority of GWAS hits are in non-coding or intergenic regions because complex disease is often caused by disturbance to biologic networks, not by isolated genes or proteins \[[@r54]\]. Regulatory SNPs can influence gene expression through several mechanisms that include the three-dimensional organization of the genome, RNA splicing, transcription factor binding, DNA methylation, and long non-coding RNAs \[[@r55],[@r56]\]. In an attempt to overcome these limitations, we used RNA-Seq. We first used the most strongly associated SNPs from the present GWASs to define chromosomal loci based on their ability to be tagged by other nearby SNPs. We then used RNA-Seq to compare gene expression between affected and unaffected dogs within these loci. Eight genes were found to be differentially expressed, and none of these genes are obvious candidates for canine PCAG. Instead, most of the genes identified have functions related to inflammation and immunity. This finding was not completely unexpected as the results of several other studies have implicated the role of inflammation and immunity in the pathogenesis of canine and human glaucoma \[[@r57]-[@r62]\]. Thus, the present results appear to corroborate these findings. However, intraocular inflammation may have occurred secondary to the onset of PCAG in the cases we used for RNA-Seq. Inflammation is a common histological finding in eyes affected by primary and secondary glaucoma, and there is no published evidence of inflammation being present in eyes considered at risk of PCAG (i.e., those with severe PLA) \[[@r63]--[@r65]\].

There are several study limitations that should be discussed. This GWAS included many fewer individuals compared to studies of complex disease in humans. In the dog, much more modest sample numbers are generally used mainly as a result of limitations in sample availability, robust phenotypic characterization, and funding. The limitations in sample availability in the present study also, unfortunately, meant it was not possible to repeat the GWAS with an additional replication set of samples. There were also limitations in the RNA-Seq investigations. The lack of ocular tissue from BHs with normal eyes meant that tissues from other breeds had to be used that represent sub-optimal control samples. Furthermore, the sequencing of RNA from multiple cell types that make up the ICA and neighboring structures could have led to a misleading pattern of differential gene expression than is actually occurring in the specific region of the ICA that is directly implicated in the pathogenesis of PCAG.

In conclusion, we successfully used GWASs to identify two novel loci associated with canine PCAG. Comparison of the gene expression profiles implicated genes involved in inflammation and immunity as involved in pathogenesis. WGS, involving multiple dogs, is likely required to elucidate candidate causal variants for canine PCAG that underlie the present GWAS findings.
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